Argus raised the firm’s price target on Boston Scientific to $95 from $80 and keeps a Buy rating on the shares. As the pandemic has ended and elective procedure volumes have recovered, Boston Scientific has seen strong results in all business segments, the analyst tells investors in a research note. Looking ahead, Boston Scientific should continue to benefit from its diverse product portfolio and commitment to innovation, with the U.S. launch of Farapulse to treat atrial fibrillation sees as the company’s key growth driver in 2024, Argus added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific participates in a conference call with JPMorgan
- Boston Scientific price target raised to $87 from $85 at Citi
- Boston Scientific price target raised to $90 from $85 at Mizuho
- Boston Scientific Welcomes New Director and Updates Governance
- Catheter Precision appoints Marie-Claude Jacques as CCO